Clinical Trials Related to Pembrolizumab

Related studies linked through entity extraction aliases.

Proton Spatially Fractionated Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With Pembrolizumab Before Surgery for the Treatment of Locally Advanced and Radiation-Naive Locoregionally Recurrent Oral Cavity Cancer, OSPRI Trial

Status: NOT_YET_RECRUITING
Phase: PHASE2

Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC

Status: RECRUITING
Phase: PHASE3

Immunotherapy and Nodal-Sparing Irradiation for T-Cell Induction and Unmasking of Tumor Antigenicity in the Microenvironment for Head and Neck Cancer

Status: NOT_YET_RECRUITING
Phase: PHASE2

Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)

Status: NOT_YET_RECRUITING
Phase: PHASE2

Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer

Status: NOT_YET_RECRUITING
Phase: PHASE2/PHASE3

Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy

Status: NOT_YET_RECRUITING
Phase: PHASE1/PHASE2

Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy

Status: NOT_YET_RECRUITING
Phase: PHASE1/PHASE2

A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants

Status: NOT_YET_RECRUITING
Phase: PHASE3

A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors

Status: RECRUITING
Phase: PHASE1/PHASE2

A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Status: NOT_YET_RECRUITING
Phase: PHASE2

A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)

Status: RECRUITING
Phase: PHASE2

NeoAdjuvant, Spare-Adjuvant (NASA) in Stage IIIB-IV (M1a) Melanoma

Status: NOT_YET_RECRUITING
Phase: PHASE2

A Study of DS-3939a in Participants With Solid Tumors

Status: NOT_YET_RECRUITING
Phase: PHASE1/PHASE2

RiMO-HNC-NEO1: Phase 2 Study of RiMO-301 and Hypofractionated Radiotherapy With Pembrolizumab for the Neoadjuvant Treatment of Resectable, Locally Advanced Head-Neck Cancer

Status: NOT_YET_RECRUITING
Phase: PHASE2

A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors

Status: NOT_YET_RECRUITING
Phase: PHASE1/PHASE2

An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

Status: RECRUITING
Phase: PHASE3

Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer

Status: NOT_YET_RECRUITING
Phase: PHASE2

Demographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Europe and Canada

Status: ACTIVE_NOT_RECRUITING
Phase: N/A

Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden

Status: NOT_YET_RECRUITING
Phase: PHASE3

Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer

Status: RECRUITING
Phase: PHASE3